Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clemastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.73 |
| ▸ | DRD3 | P35462 | 5/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.73 |
| ▸ | HTR1A | P08908 | 4/20 | 0.73 |
| ▸ | DRD1 | P21728 | 4/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clemastine SCHEMBL28193835 | 1.00 | CHRM2 (0.73) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL6904801 | 0.90 | DRD2 (0.64) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL4178 | 0.86 | CHRM3 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL4058472 | 0.86 | CHRM3 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL4087919 | 0.86 | CHRM3 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL23785539 | 0.86 | CHRM3 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL727373 | 0.86 | CHRM3 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL23785540 | 0.86 | CHRM3 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL10625327 | 0.85 | CHRM2 (0.65) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 | |
| Clemastine SCHEMBL932384 | 0.84 | CHRM3 (0.98) | CHRM2SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107530494-A | Injection system with storage compartment | 希普罗特克有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107530493-A | Injecting systems with storage compartment | 希普罗特克有限公司 | 2018-01-02 | — | — | CN | disclosed |
| EP-1438031-B1 | ORALLY ADMINISTERED LIQUID COMPOSITIONS COMPRISING GUAIFENESIN AND A POLYOXYALKYLENE BLOCK COPOLYMER | PROCTER & GAMBLE (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7138133-B2 | Orally administered liquid compositions | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1438031-A1 | ORALLY ADMINISTERED LIQUID COMPOSITIONS COMPRISING GUAIFENESIN AND A POLYOXYALKYLENE BLOCK COPOLYMER | THE PROCTER & GAMBLE COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030113377-A1 | Orally administered liquid compositions | PROCTER & GAMBLE COMPANY, THE | 2003-06-19 | — | — | US | disclosed |
| WO-2003030877-A1 | ORALLY ADMINISTERED LIQUID COMPOSITIONS COMPRISING GUAIFENESIN AND A POLYOXYALKYLENE BLOCK COPOLYMER | THE PROCTER & GAMBLE COMPANY (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030113377-A1 | Orally administered liquid compositions | PGA5, CYP2C19, CYP3A7 | HRH1 1468/4885CHRM2 1404/4885SLC6A2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.